Navigation Links
New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families
Date:3/20/2011

master regulators of gene expression associated with many diseases. Because they dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets in the treatment of many disease processes.

"Using tiny LNA-based compounds to successfully inhibit entire disease-associated microRNA families provides a new range of opportunities to develop novel microRNA-targeted drugs for both in-house drug discovery programs, as well as with our partners," said Henrik rum, Ph.D., Vice President and Chief Scientific Officer of Santaris Pharma A/S. "The versatility of our proprietary LNA Drug Platform has the potential to develop new modalities to target a broad range of diseases, including cardiometabolic disorders, infectious and inflammatory diseases, and cancer by targeting microRNAs, entire microRNA families or messengerRNAs."

The study published in Nature Genetics was carried out by Santaris Pharma A/S scientists and collaborators at Cold Spring Harbor Laboratory, New York. In this study, scientists demonstrated that tiny LNA-based compounds inhibited both single microRNAs and entire microRNA families in cultured cells, as well as in vivo in several mice tissues and in a mouse breast tumor model. The tiny LNA-based compounds were well tolerated by the mice and could be delivered without the use of complex delivery vehicles.

The Santaris Pharma A/S LNA Drug Platform is the only RNA technology with both mRNA and microRNA targeted drugs in clinical trials, demonstrating the broad utility of the proprietary platform. In September 2010, Santaris Pharma A/S successfully advanced miravirsen, a lead microRNA drug candidate targeting miR-122, into Phase 2 studies for the treatment of patients infected with the Hepatitis C virus. In addition, Santaris Pharma A/S is advancing two mRNA-targeted drugs, SPC5001 targeting PCSK9 and SPC4955 targeting apoB, for the treatment of high cholesterol into Phase 1 in the first hal
'/>"/>

Contact: Navjot Rai
navjot.rai@santaris.com
858-764-7064 x206
Edelman PR
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. High school students paper published in prestigious college math journal
2. Results of the third school nutrition dietary assessment study published
3. Special issue Comparative Cognition in Context now published
4. Nutrigenomics -- developing personalized diets for disease prevention -- part 2 just published in OMICS
5. Major aspergillus genomics supplement published by journal Fungal Genetics and Biology
6. Ambati study published in PNAS
7. First comprehensive guidelines for managing medullary thyroid carcinoma published in Thyroid journal
8. Data published in the New England Journal of Medicine support use of raxibacumab (ABthrax) for the treatment of inhalation anthrax
9. University of Hawaii at Manoa professor published in science journal
10. New Report Just Published: World Solid-State, Fiber, Gas and Dye Lasers Market Report
11. Reviews of microbial gene language published in special issue of Trends in Microbiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... new systematic assessment of malnutrition, created by researchers at ... providers in diagnosis and treatment. Up to 50 ... estimated to be malnourished, according to Gordon Jensen, professor ... is widespread, confusion exists in the clinical community on ...
... society to reflect it, says Case Western Reserve University,s ... of thinking about reversing the tide of climate change. ... emissions, changing light bulbs or even developing new technologies ... climate change is societal, born of civic protest against ...
... New findings presented at Europe,s leading breast cancer translational ... many biological differences between individual breast cancers. ... or less sensitive to important therapies, the new studies ... appropriate treatment for millions of patients. "Despite major ...
Cached Biology News:Researchers unveil new assessment for diagnosing malnutrition 2'Ethical Adaptation to Climate Change' envisions the good life in a harsher world 2'Ethical Adaptation to Climate Change' envisions the good life in a harsher world 3New data improve understanding of breast cancer's multiple varieties 2New data improve understanding of breast cancer's multiple varieties 3New data improve understanding of breast cancer's multiple varieties 4New data improve understanding of breast cancer's multiple varieties 5New data improve understanding of breast cancer's multiple varieties 6
(Date:6/3/2015)... MINNETONKA, Minn. , June 3, 2015 ... company that supports the entire spectrum of clinical research, ... its iMedNet eClinical technology platform ... customers by the end of this month.  iMedNet ... system – built from the ground up by MedNet ...
(Date:6/3/2015)... , June 3, 2015 ... a specialty biopharmaceutical company focused on allergy, today announces ... novel immunotherapy candidates targeting house dust mite, grass and ... Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting ... 6-10 June. Sunday, 7 June 2015 ,Oral ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Photo-Eyewear™ ( ... its name to PogoTec™, Inc. ( http://www.PogoTec.com ) ... electronic wearable device products and technologies it is developing ... of three business divisions, PogoTec™ will provide focused resources ... as follows: , , On-Track™ – ...
(Date:6/3/2015)... Global Stem Cells Group and its ... conduct Romania’s first ever stem cells harvesting and reintegration ... Stem Cell Training, Inc., Cosmetic Surgeon Morad Iancu, ... Stem Cell Training Course for medical professionals in Bucharest. ... in Bucharest and Tel Aviv, Israel, and a popular ...
Breaking Biology Technology:MedNet Announces "2015 Feature 1" Release Of iMedNet eClinical 2Circassia to Present at EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015 2Circassia to Present at EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015 3Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3
... deCODE genetics,Inc. (Nasdaq: DCGN ) today announced that ... press release to be issued on Thursday, May 1,after the ... host a live,webcast of its conference call to discuss these ... Eastern Time/12 noon GMT/1pm,British Summer Time., The webcast can ...
... Schering-Plough,Corporation announced today that Chairman and CEO Fred ... or 110, 000 shares at,an average purchase price of ... announced my intention to purchase these shares in,January, this ... its products -- including ZETIA and VYTORIN --,and our ...
... Board of,Directors of Shire plc (LSE: SHP) (NASDAQ: ... today that Michael Rosenblatt M.D.,will join the Board ... Dr Rosenblatt is the Dean of Tufts University ... of Medicine at Harvard,Medical School and has served ...
Cached Biology Technology:deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results 2Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 2Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 3Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 4